Semax Dosage in the Research Literature: Routes, Protocols, and Stability
Semax dosage as documented in the published research literature: intranasal vs subcutaneous routes, Russian clinical protocols, cycling studies, storage stability, and pharmacokinetics.
Semax Dosage in the Research Literature
Semax dosage documentation in the published literature spans rodent preclinical work, in vitro assays, and a limited body of Russian clinical protocols. This page indexes what doses were administered, by which route, in which species or study type. It does not constitute dosage guidance for any human use.
Research dose ranges for Semax in rodent studies: 30-250 µg/kg intranasal in behavioral and neurotrophin studies;[1][2][3] 100 µg/kg intraperitoneal in rat ischemia models;[4][5] 0.05 mg/kg (50 µg/kg) intranasal in developmental and stress models.[12][13] Russian clinical stroke protocols describe 1-2 mg/day as a 1% intranasal spray in 10-day courses, based on observational clinical data.[15]
Semax Nasal Spray: Administration in Research Models
Semax nasal spray is the primary administration route studied in Eastern European clinical and pre-clinical trials, enabling direct CNS access via the olfactory mucosa.[9]
Shevchenko et al. (2006) measured the pharmacokinetics of intranasal Semax in rats: 0.093% of total radioactivity per gram was detected in the brain at 2 minutes post-dose, with approximately 80% representing intact Semax peptide and the remainder the Pro-Gly-Pro tripeptide metabolite.[9] This 2-minute brain-entry time is notably fast — consistent with olfactory transport pharmacokinetics, which bypass the blood-brain barrier via direct axonal transport from olfactory receptor neurons to the olfactory bulb.
What is Semax nasal spray, and how is it used in research? Intranasal delivery is the primary route studied in Eastern European clinical and pre-clinical trials, enabling direct CNS access via the olfactory mucosa.[9] In Russian clinical stroke protocols, 1% nasal spray preparations at approximately 1-2 mg/day in 10-day courses have been described in observational reports.[15]
Intranasal vs subcutaneous Semax: Intranasal delivery reaches peak CNS concentration faster in rat models (detectable at 2 minutes);[9] subcutaneous administration produces longer systemic exposure in comparative pharmacokinetic work. Route comparisons are largely from Russian-language pre-clinical literature. The intranasal route dominates the published research record.
Semax half-life and duration of action
Semax half-life and duration of action: parent peptide half-life is approximately 2-5 minutes in plasma based on enzymatic degradation kinetics; active metabolites extend neurological effects to several hours in rodent models.[9]
The parent peptide undergoes rapid enzymatic degradation by serum and tissue peptidases. The primary metabolite is Pro-Gly-Pro (PGP), which retains independent neurotrophin-activating properties and has been characterized in ischemia models. The neurological activity of Semax in rodent behavioral studies extends substantially beyond the parent peptide's plasma half-life, likely because: (1) the PGP metabolite sustains downstream neurotrophin activation, and (2) BDNF transcription, once initiated via cAMP/CREB signaling, continues after peptide clearance.
How long does Semax last? Parent peptide plasma half-life is short (minutes); however, behavioral and neurotrophin effects in rodent models persist for hours after a single dose — a duration inconsistent with parent-peptide kinetics alone and attributed to metabolite activity and downstream BDNF/TrkB signaling cascade duration.[9][17]
How quickly does Semax work? CNS activity markers appear within 15-30 minutes of intranasal dosing in rat models, consistent with olfactory transport pharmacokinetics.[9] In the Dolotov et al. BDNF studies, significant BDNF protein elevation was detected at 3 hours post-intranasal dosing.[1]
Cycling protocols in Semax research
Russian clinical protocols typically describe 10-14 day courses with off periods. The Russian approved drug protocol for ischemic stroke describes courses of 10 days at 1% nasal spray concentrations.[15] The pharmacological rationale for cycling is not fully characterized in the Western literature.
The question of whether receptor downregulation drives cycling requirements is unresolved. MC4R downregulation kinetics under sustained Semax exposure have not been quantified in any published study identified in this review. The cycling pattern in Russian clinical practice may reflect empirical dosing observations rather than a characterized receptor-adaptation mechanism.
Semax storage and stability
Does Semax need to be refrigerated? Peptide stability studies recommend refrigerated storage at 2-8°C for aqueous solutions; lyophilized powder is stable at room temperature for shorter periods.[17][18] Light exposure and repeated freeze-thaw cycles degrade peptide activity.
Shevchenko et al. (2013) examined the proteolytic stability of N-acetylated Semax analogs, characterizing leucyl aminopeptidase and microsomal enzyme degradation pathways.[18] N-acetylation at the N-terminus reduces susceptibility to aminopeptidase cleavage — the primary degradation mechanism for the parent compound. C-terminal amidation (as in N-Acetyl Semax Amidate) additionally blocks carboxypeptidase cleavage of the C-terminal Pro residue.
Standard peptide storage guidance applies: reconstituted solutions should be used promptly or stored at -20°C in single-use aliquots to avoid freeze-thaw degradation. Aqueous solutions at 2-8°C are appropriate for short-term working stock. Lyophilized powder is more stable at room temperature for periods of weeks, but extended room-temperature storage is not recommended.
For information on modified analogs with improved stability, see N-Acetyl Semax Amidate variants.
Onset of Semax effects in research models
Onset of Semax effects in research models: CNS activity markers appear within 15-30 minutes of intranasal dosing in rat models, consistent with olfactory transport pharmacokinetics.[9]
In the Shevchenko et al. (2006) kinetics study, intact Semax was detectable in rat brain tissue at 2 minutes, with 80% of recovered radioactivity representing the parent peptide.[9] The Shadrina et al. (2001) glial cell culture study measured an 8-fold BDNF mRNA increase within 30 minutes of Semax treatment in vitro.[7] In the 2025 calcium-signaling study, Semax at 1 µM produced detectable changes in spontaneous Ca2+ fluctuation frequency in hippocampal slices during the observation window of the experiment.[19]
The Shadrina et al. (2010) in vivo study noted that BDNF and NGF mRNA changes showed region-specific temporal patterns: initial decreases at 20 minutes in hippocampus and retina, followed by increases in frontal cortex and retinal recovery at 90 minutes.[8] This multidirectional temporal profile underscores that Semax onset is not a uniform step-function — it is a cascade of region-specific transcriptional events extending from minutes to hours.